Last reviewed · How we verify

Intrathecal Baclofen Pump

Amsterdam UMC, location VUmc · Phase 2 active Small molecule

Intrathecal Baclofen Pump is a GABA receptor agonist Small molecule drug developed by Amsterdam UMC, location VUmc. It is currently in Phase 2 development for Spasticity. Also known as: intrathecal baclofen treatment.

GABA_B receptor agonist

GABA_B receptor agonist Used for Spasticity.

Likelihood of approval
12.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • CNS / neurology attrition -3.0pp
    CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameIntrathecal Baclofen Pump
Also known asintrathecal baclofen treatment
SponsorAmsterdam UMC, location VUmc
Drug classGABA receptor agonist
TargetGABA_B receptor
ModalitySmall molecule
Therapeutic areaNeurology
PhasePhase 2

Mechanism of action

Baclofen acts as an agonist at the GABA_B receptor, which is involved in the regulation of muscle tone and spasticity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intrathecal Baclofen Pump

What is Intrathecal Baclofen Pump?

Intrathecal Baclofen Pump is a GABA receptor agonist drug developed by Amsterdam UMC, location VUmc, indicated for Spasticity.

How does Intrathecal Baclofen Pump work?

GABA_B receptor agonist

What is Intrathecal Baclofen Pump used for?

Intrathecal Baclofen Pump is indicated for Spasticity.

Who makes Intrathecal Baclofen Pump?

Intrathecal Baclofen Pump is developed by Amsterdam UMC, location VUmc (see full Amsterdam UMC, location VUmc pipeline at /company/amsterdam-umc-location-vumc).

Is Intrathecal Baclofen Pump also known as anything else?

Intrathecal Baclofen Pump is also known as intrathecal baclofen treatment.

What drug class is Intrathecal Baclofen Pump in?

Intrathecal Baclofen Pump belongs to the GABA receptor agonist class. See all GABA receptor agonist drugs at /class/gaba-receptor-agonist.

What development phase is Intrathecal Baclofen Pump in?

Intrathecal Baclofen Pump is in Phase 2.

What are the side effects of Intrathecal Baclofen Pump?

Common side effects of Intrathecal Baclofen Pump include Drowsiness, Nausea, Dizziness.

What does Intrathecal Baclofen Pump target?

Intrathecal Baclofen Pump targets GABA_B receptor and is a GABA receptor agonist.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing